Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $8.00 by Analysts at Guggenheim

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target trimmed by Guggenheim from $12.00 to $8.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts also recently weighed in on ZNTL. Oppenheimer reiterated an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target for the company in a research report on Monday, August 12th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock opened at $3.05 on Friday. The firm has a 50-day simple moving average of $3.42 and a two-hundred day simple moving average of $5.33. The company has a market cap of $217.34 million, a P/E ratio of -1.22 and a beta of 1.74. Zentalis Pharmaceuticals has a fifty-two week low of $2.66 and a fifty-two week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. Equities research analysts forecast that Zentalis Pharmaceuticals will post -2.76 EPS for the current year.

Institutional Trading of Zentalis Pharmaceuticals

Large investors have recently bought and sold shares of the business. Anfield Capital Management LLC purchased a new stake in Zentalis Pharmaceuticals during the 2nd quarter valued at about $40,000. Erste Asset Management GmbH purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at about $37,000. Paloma Partners Management Co purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at about $37,000. Aigen Investment Management LP purchased a new stake in Zentalis Pharmaceuticals during the 3rd quarter valued at about $41,000. Finally, Kennedy Capital Management LLC purchased a new stake in Zentalis Pharmaceuticals during the 1st quarter valued at about $189,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.